Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Browse Research
  • Browse News
  • About Our Research
  • Transplant Enews

  • Research and News
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020
- Collapse

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • Updated evidence-based guidelines for optimal selection of unrelated donors and cord blood units for HCT

    September 2019

    Dehn J, et al., Blood – A panel of immunogeneticists and other experts in the field of hematopoietic cell transplantation (HCT) has published updated evidence-based guidelines for the optimal selection of unrelated donors and cord blood units used for transplants.

    The updated guidelines make recommendations for both HLA and non-HLA factors to consider in graft selection, including donor availability, donor age, patient sensitivity to HLA antigens, natural killer (NK) cell alloreactivity, and minimum total nucleated cell doses and CD34+ cell doses for cord blood units.

     

    Read More

  • Expert Panel Issues Practical “How To” Guide on Optimal Cord Blood Transplantation

    August 2017
    Barker JN, et al. Biol Blood Marrow Transplant – Two leading transplant organizations have joined together to publish a report on optimal practices in cord blood transplantation (CBT), including a state-of-the-art clinical “how to” guide on CBT.

    Read More

  • Is Cord Blood the Best Alternative Graft Source for Patients with Minimal Residual Disease?

    October 2016
    Milano F, et al. N Engl J Med – A retrospective study of 582 patients with acute leukemia or myelodysplastic syndromes has shown that umbilical cord blood may be a superior graft choice for the approximately 70% of patients who lack an HLA-matched related donor, especially if they are minimal residual disease positive (MRD+).

    Read More

  • One-Year OS of 86% Achieved with Unrelated Donor HCT for Children with SCD

    October 2016
    Shenoy S, et al Blood – This multi-center phase II trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) analyzed outcomes of 29 children (age range 6-19 years) with sickle cell disease (SCD) who underwent reduced-intensity conditioning unrelated donor hematopoietic cell transplantation (HCT) between 2008 and 2014.

    Read More

  • 95% One-Year HCT Survival for Adults with Sickle Cell Disease

    December 2015
    Krishnamurti L, et al. ASH abstract oral presentation, December 2015 – One-year overall and event-free survival probabilities were both 95% after hematopoietic cell transplantation (HCT) in adults with sickle cell disease (SCD), according to results of a multi-center study reported at the ASH Annual Meeting.

    Read More

  • Parallel Phase 2 Trials Confirm Utility of Both Haploidentical and Cord Blood HCT

    July 2011
    Brunstein CG, et al. Blood – Two concurrent multi-center phase 2 studies have confirmed the utility of using unrelated double umbilical cord blood (dUCB) or HLA-haploidentical donor bone marrow grafts in reduced-intensity hematopoietic cell transplantation (HCT).

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2021 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020